Aspergillosis Clinical Trial
Official title:
A Phase III, Double Blind, Randomized Study to Evaluate Safety and Efficacy of BAL8557 Versus Voriconazole for Primary Treatment of Invasive Fungal Disease Caused by Aspergillus Species or Other Filamentous Fungi.
The purpose of this study is to compare the efficacy and safety of isavuconazole versus voriconazole in the treatment of patients with invasive aspergillosis.
Acute invasive fungal infections caused by aspergillus, zygomycetes and other filamentous fungi remain life threatening diseases. Early treatment with highly effective anti-fungals reduces mortality. This study investigates the efficacy and safety of isavuconazole in the treatment of invasive fungal diseases, caused by Aspergillus or other filamentous fungi. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Suspended |
NCT01887457 -
Individualisation of Voriconazole Antifungal Therapy Antifungal Therapy
|
Phase 2 | |
| Completed |
NCT00940017 -
A Study To Assess The Anidulafungin And Voriconazole Concentration In Lung Following Intravenous Administration In Healthy Subjects
|
Phase 4 | |
| Enrolling by invitation |
NCT01617759 -
Aspergillus-specific PCR Assay in Cerebrospinal Fluid Samples for Detection of Central Nervous System Aspergillosis
|
||
| Terminated |
NCT03905447 -
The Effect of Early Treatment of PC945 on Aspergillus Fumigatus Lung Infection in Lung Transplant Patients.
|
Phase 2 | |
| Recruiting |
NCT04744454 -
Post Marketing Surveillance (PMS) Study of Cresemba in Korea.
|
||
| Completed |
NCT02715570 -
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of PC945
|
Phase 1 | |
| Withdrawn |
NCT01622595 -
UARK 2009-99 A Non-interventional Observational Study of Infectious Complications in Cancer Patients
|
N/A | |
| Completed |
NCT00001937 -
Comparing the Effectiveness of Fluconazole and a New Medicine (FK463) in Preventing Fungal Infections in Bone Marrow Transplant Patients
|
Phase 3 | |
| Completed |
NCT04935463 -
Mucormycosis in COVID-19
|
||
| Withdrawn |
NCT01188759 -
Voriconazole And Anidulafungin Combination For Invasive Aspergillosis In Pediatric Subjects
|
Phase 3 | |
| Completed |
NCT00473252 -
Surveillance of Fungal Infections During Construction Activity
|
N/A | |
| Completed |
NCT00037206 -
A Safety & Effectiveness Study of Intravenous Anidulafungin With AmBisome® for Treatment of Invasive Aspergillosis (IA).
|
Phase 2/Phase 3 | |
| Completed |
NCT04818853 -
COVID-19 Associated Pulmonary Aspergillosis (CAPA) and Other Invasive Fungal Infections (IFI)
|
||
| Recruiting |
NCT06135597 -
Immune Regulation in Chronic Aspergillus Infection After COVID-19 Infection
|
||
| Terminated |
NCT02646800 -
Post Marketing Study to Evaluate the Safety and Efficacy of Micafungin Against Fungal Infections Caused by Candida Spp or Aspergillus Spp
|
Phase 4 | |
| Completed |
NCT00854607 -
An Observational Study of Fungal Biomarkers (MK-0000-089)
|
N/A | |
| Completed |
NCT00388167 -
Acetato de Caspofungin (Cancidas®) in the Treatment of Fungal Infection
|
Phase 4 | |
| Completed |
NCT05065658 -
Posaconazole Prophylaxis for CAPA Prevention in Critically-Ill Patients
|
||
| Completed |
NCT00005912 -
Voriconazole to Prevent Systemic Fungal Infections in Children
|
Phase 1 | |
| Completed |
NCT04431804 -
THYME AND CARVACROLL Nanoparticle Effect on Fungi
|